BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hepatitis
,
Prostate
,
Alcohol
,
Lovastatin
,
rs6983267
,
BRCA1
,
Metabolism of xenobiotics
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
CHI3L2
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Salivary gland
Parotid gland
Thymus gland
B lymphocyte (naive) of spleen
Tongue superior part with papillae
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
M2 macrophage marker CHI3L2 could serve as a potential prognostic and immunological biomarker in gli…
CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progress…
Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survi…
YKL-39 as a Potential New Target for Anti-Angiogenic Therapy in Cancer.
A sex-stratified analysis of neuroimmune gene expression signatures in Alzheimer's disease brains.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for CHI3L2
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ